- Trials with a EudraCT protocol (3)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
3 result(s) found for: External iliac artery.
Displaying page 1 of 1.
EudraCT Number: 2014-005569-58 | Sponsor Protocol Number: BAY59-7939/17454 | Start Date*: 2015-09-23 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular event... | |||||||||||||
Medical condition: Peripheral artery disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) ES (Completed) HU (Completed) GB (Completed) FR (Completed) PT (Completed) SE (Completed) BE (Completed) BG (Completed) DK (Completed) DE (Completed) NL (Completed) PL (Completed) SK (Completed) LT (Completed) LV (Completed) RO (Completed) EE (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013157-15 | Sponsor Protocol Number: 1218.74 | Start Date*: 2010-10-14 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm.V | |||||||||||||
Full Title: A multicentre, international, randomised, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high ca... | |||||||||||||
Medical condition: Patients with documented diagnosis of T2DM with insufficient glycaemic control and at high risk of CV events prior to informed consent can be enrolled in the study. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) DE (Completed) PT (Completed) CZ (Completed) ES (Completed) IE (Completed) FI (Completed) SE (Completed) GB (Completed) SK (Completed) IT (Completed) GR (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002467-26 | Sponsor Protocol Number: 480-SFA2013-001 | Start Date*: 2013-08-30 |
Sponsor Name:480 Biomedical, Inc. | ||
Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions | ||
Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
